作者:Xiaojun Zeng、Wenhao Yan、Samson B. Zacate、Tzu-Hsuan Chao、Xiaodong Sun、Zhi Cao、Kate G. E. Bradford、Matthew Paeth、Sam B. Tyndall、Kundi Yang、Tung-Chun Kuo、Mu-Jeng Cheng、Wei Liu
DOI:10.1021/jacs.9b05363
日期:2019.7.24
We report herein a highly efficient Cu-catalyzed protocol for the conversion of aliphatic carboxylic acids to the corresponding difluoromethylated analogues. This robust, operationally simple and scalable protocol tolerates a variety of functional groups and can convert a diverse array of acid-containing complex molecules to the alkyl-CF2H products. Mechanistic studies support the involvement of alkyl
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase
作者:Katherine A. Hurley、Thiago M. A. Santos、Molly R. Fensterwald、Madhusudan Rajendran、Jared T. Moore、Edward I. Balmond、Brice J. Blahnik、Katherine C. Faulkner、Marie H. Foss、Victoria A. Heinrich、Matthew G. Lammers、Lucas C. Moore、Gregory D. Reynolds、Galen P. Shearn-Nance、Brian A. Stearns、Zi W. Yao、Jared T. Shaw、Douglas B. Weibel
DOI:10.1039/c7md00012j
日期:——
potent inhibitors of DNA gyrase and are activeagainst clinical strains of Gram-negativebacteria (Escherichia coli, Shigella flexneri, and Salmonella enterica; 3 of 10 wild-type strains tested) and Gram-positive bacteria (Bacillus spp., Enterococcus spp., Staphylococcus spp., and Streptococcus spp.; all 9 of the wild-type strains tested). E. coli strains resistant to the DNA gyrase inhibitors ciprofloxacin
[EN] LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE LACTAME UTILES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE
申请人:ACTELION PHARMACEUTICALS LTD
公开号:WO2012063207A1
公开(公告)日:2012-05-18
The present invention relates to lactam derivatives of formula (I) wherein Y, R1, R2 and R3 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.
The invention provides compounds of formula la, lb and Ic: [Formula Ia, Ib, and Ic] and salts thereof, wherein variables are as described in the specification, as well as compositions comprising a compound of formula Ia-Ic, methods of making such compounds, and methods of using such compounds, e.g., as inhibitors of bacterial RNA polymerase and as antibacterial agents.
Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
申请人:Boehringer Ingelheim Pharmaceuticals, Inc.
公开号:US20040180922A1
公开(公告)日:2004-09-16
Disclosed are compounds of formula (I):
1
wherein R
1
and R
2
are defined herein, which are useful as inhibitors of the kinase activity of the I&kgr;B kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.